Diabetes mellitus
A recent study published in the journal Diabetes & Metabolism has found that the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) can reduce the risk of hepatocellular carcinoma (HCC) and all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2D). The research, conducted by
Diabetes mellitus
A recent study published in the journal Diabetes & Metabolism has found that the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) can reduce the risk of hepatocellular carcinoma (HCC) and all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2D). The research, conducted by
Diabetes therapy
Researchers at the Indian Institute of Technology Guwahati have made a significant advancement in the production of recombinant human insulin using novel promoters in Pseudomonas fluorescens. The study aimed to develop an IPTG-free expression system, which is crucial for large-scale production of insulin. The research demonstrated the use of constitutive
Diabetes mellitus
A recent study published in the journal Diabetes & Metabolism has found that the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) can reduce the risk of hepatocellular carcinoma (HCC) and all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2D). The research, conducted by
Diabetes mellitus
Research from the University of California Los Angeles (UCLA) has highlighted the potential risks associated with the use of glucose elevating agents, such as glucagon-like peptide-1 receptor agonists, in patients undergoing elective procedures with general anesthesia. The study, published in the Journal of Ect, noted that these medications can cause
Diabetes mellitus
A recent study on type 2 diabetes in adolescents has highlighted the need for self-management among young patients with the condition. Research conducted at Mahidol University in Bangkok, Thailand, aimed to explore the experiences of adolescents with type 2 diabetes mellitus (T2DM) and provide insights for developing tailored management programs.
Diabetes mellitus
A recent study on type 2 diabetes in adolescents has highlighted the need for self-management among young patients with the condition. Research conducted at Mahidol University in Bangkok, Thailand, aimed to explore the experiences of adolescents with type 2 diabetes mellitus (T2DM) and provide insights for developing tailored management programs.
Diabetes mellitus
Research from the University of California Los Angeles (UCLA) has highlighted the potential risks associated with the use of glucose elevating agents, such as glucagon-like peptide-1 receptor agonists, in patients undergoing elective procedures with general anesthesia. The study, published in the Journal of Ect, noted that these medications can cause
Diabetes mellitus
Researchers at Emory University have found that diabetes mellitus significantly increases the risk of emergency room visits and hospital admissions. According to the study, inpatient hyperglycemia in patients with or without diabetes mellitus is associated with a higher rate of complications, longer hospital stays, and increased mortality compared to patients
Diabetes therapy
Researchers from Gachon University have discussed the latest findings in drug research, highlighting the potential of carbon dots (CDs) in treating and managing diabetes. According to the study, diabetes mellitus is a prevalent and challenging disease worldwide, with a rising global prevalence despite advances in therapeutic options and management strategies.
Adults
Research on the synergistic effects of diabetes and sarcopenic obesity on cardiovascular disease risk in Chinese adults has been published. The study aimed to evaluate the individual and combined impacts of these two conditions on cardiovascular disease risk in middle-aged and elderly Chinese adults. A total of 10,478 participants
Diabetes therapy
According to a recent study published in Current Atherosclerosis Reports, glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as a multifaceted therapeutic option for addressing cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH). These medications, originally developed for glycemic control in diabetes mellitus (DM), are now being explored for their
